The p53 protein, frequently referred to as the "guardian of the genome," regulates the cell cycle, facilitates DNA repair, and triggers apoptosis in response to genetic damage, all of which are vital functions that preserve cellular integrity. Because p53 has major implications for cancer biology, treatment, and prevention, research on p53 mutations is crucial. The tumor suppressor gene p53 produces a protein that is essential for halting the development of cancer. It helps monitoring of the genome's integrity. When DNA damage occurs, p53 can cause apoptosis or cell cycle arrest, depending on whether the damage can be repaired or is irreversible. This dual function serves as a barrier against the growth of tumors by halting the division of cells that contain genetic abnormalities.
Comprehending the pathways by which p53 mutations lead to cancer can help create new approaches for treatment. For example, as possible cancer therapeutics, tiny compounds that can mimic or reactivate mutant p53's action are being investigated. Furthermore, treatments that take advantage of the deficiencies present in p53-deficient tumors, like synthetic lethality strategies, present encouraging directions for intervention. Additionally, studies on p53 mutations have important diagnostic and prognostic implications. Finding the mutations can therefore aid in customising therapy regimens and enhancing patient outcomes. Despite its significance, p53 research has several obstacles. The variety of p53 mutations and their context-dependent effects make it more difficult to find treatments that work for all. Furthermore, the investigation of p53 becomes more intricate due to its interplay with other cellular pathways. With the use of cutting-edge methods like single-cell sequencing and CRISPR-Cas9 gene editing, which can offer more accurate and thorough insights into p53 activities and mutations, future research attempts to untangle these intricacies.
p53 plays a crucial role in anti-tumor immunity by regulating various elements such as TRAIL, DR5, TLRs, Fas, PKR, ULBP1/2, CCL2, the T-cell inhibitory ligand PD-L1, pro-inflammatory cytokines, immune cell activation states, and antigen presentation. Genetic alterations in p53 can lead to immune evasion by affecting immune cell recruitment to the tumor, cytokine secretion within the tumor microenvironment (TME), and inflammatory signaling pathways. In certain cases, p53 mutations increase the neoantigen load, enhancing the response to immune checkpoint inhibitors. Therapeutic restoration of mutated p53 can reinstate anti-cancer immune cell infiltration and reduce pro-tumor signaling, promoting tumor regression. Clinical evidence suggests that restoring p53 can trigger an anti-cancer immune response in immunologically cold tumors. Clinical trials combining p53-restoring compounds or p53-based vaccines with immunotherapy have shown anti-tumor immune activation and tumor regression, with varying results across different cancer types.
p53 mutations are present in around half of all human malignancies, demonstrating the protein's vital role in cancer biology. The possibility of creating tailored treatments that might either lessen the impacts of p53 depletion or restore its normal function highlights the importance of p53 research and our proposed topic.
Overall, the significance of ongoing research in this field is highlighted by its pivotal function in tumor suppression, the high frequency of its mutations in cancer, and the potential for generating targeted therapeutics. Understanding p53 better would improve not only the prevention and treatment of cancer but also our understanding of cellular biology and disease pathways in general.
Keywords:
p53 mutation, breast cancer, gain-of-function, therapy, tumor suppression, TNBC, Signaling Pathways
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The p53 protein, frequently referred to as the "guardian of the genome," regulates the cell cycle, facilitates DNA repair, and triggers apoptosis in response to genetic damage, all of which are vital functions that preserve cellular integrity. Because p53 has major implications for cancer biology, treatment, and prevention, research on p53 mutations is crucial. The tumor suppressor gene p53 produces a protein that is essential for halting the development of cancer. It helps monitoring of the genome's integrity. When DNA damage occurs, p53 can cause apoptosis or cell cycle arrest, depending on whether the damage can be repaired or is irreversible. This dual function serves as a barrier against the growth of tumors by halting the division of cells that contain genetic abnormalities.
Comprehending the pathways by which p53 mutations lead to cancer can help create new approaches for treatment. For example, as possible cancer therapeutics, tiny compounds that can mimic or reactivate mutant p53's action are being investigated. Furthermore, treatments that take advantage of the deficiencies present in p53-deficient tumors, like synthetic lethality strategies, present encouraging directions for intervention. Additionally, studies on p53 mutations have important diagnostic and prognostic implications. Finding the mutations can therefore aid in customising therapy regimens and enhancing patient outcomes. Despite its significance, p53 research has several obstacles. The variety of p53 mutations and their context-dependent effects make it more difficult to find treatments that work for all. Furthermore, the investigation of p53 becomes more intricate due to its interplay with other cellular pathways. With the use of cutting-edge methods like single-cell sequencing and CRISPR-Cas9 gene editing, which can offer more accurate and thorough insights into p53 activities and mutations, future research attempts to untangle these intricacies.
p53 plays a crucial role in anti-tumor immunity by regulating various elements such as TRAIL, DR5, TLRs, Fas, PKR, ULBP1/2, CCL2, the T-cell inhibitory ligand PD-L1, pro-inflammatory cytokines, immune cell activation states, and antigen presentation. Genetic alterations in p53 can lead to immune evasion by affecting immune cell recruitment to the tumor, cytokine secretion within the tumor microenvironment (TME), and inflammatory signaling pathways. In certain cases, p53 mutations increase the neoantigen load, enhancing the response to immune checkpoint inhibitors. Therapeutic restoration of mutated p53 can reinstate anti-cancer immune cell infiltration and reduce pro-tumor signaling, promoting tumor regression. Clinical evidence suggests that restoring p53 can trigger an anti-cancer immune response in immunologically cold tumors. Clinical trials combining p53-restoring compounds or p53-based vaccines with immunotherapy have shown anti-tumor immune activation and tumor regression, with varying results across different cancer types.
p53 mutations are present in around half of all human malignancies, demonstrating the protein's vital role in cancer biology. The possibility of creating tailored treatments that might either lessen the impacts of p53 depletion or restore its normal function highlights the importance of p53 research and our proposed topic.
Overall, the significance of ongoing research in this field is highlighted by its pivotal function in tumor suppression, the high frequency of its mutations in cancer, and the potential for generating targeted therapeutics. Understanding p53 better would improve not only the prevention and treatment of cancer but also our understanding of cellular biology and disease pathways in general.
Keywords:
p53 mutation, breast cancer, gain-of-function, therapy, tumor suppression, TNBC, Signaling Pathways
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.